Inactive Instrument

Highlights Mira IV Acquisition Corp Toronto S.E.

Equities

MRYp

CA60456Q1054

End-of-day quote Toronto S.E. Other stock markets
-	-

05-15	Transcript : Profound Medical Corp. - Shareholder/Analyst Call
05-14	Sector Update: Health Care Stocks Steady Premarket Tuesday	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Tuesday	05-14	MT
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module	05-14	MT
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan	05-14	MT
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan	05-14	CI
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance	05-09	MT
Profound Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue	05-09	MT
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance	05-09	MT
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024	05-09	CI
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer	05-06	MT
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"	05-06	MT
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"	05-06	MT
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment	03-07	MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer	03-07	MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share	03-07	MT
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure	02-27	MT
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers	02-27	CI
Profound Medical Brief: Entering Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure	02-27	MT
Profound Medical Brief: Adds Top priorities for 2024 will be to further increase Its TULSA-PRO installed base, support increased system utilization, complete its ongoing Level 1 CAPTAIN trial	01-03	MT
Profound Medical Brief: For Full year 2023, Anticipates total revenues to be in Approximate range of US$7.1 million to $7.2 million	01-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mira IV Acquisition Corp Toronto S.E.

Equities

MRYp

CA60456Q1054

Highlights

Filters